Cell Precision, LLC

Georgia Tech Research Corporation

Emory University

Other

W Robert Taylor

Michael L Wach

Raymond P Vito

Jack C Griffis, Iii

Niren Murthy

Sarah F Knight

Kousik Kundu

Kenneth A Gall

David Lee Safranski

Jonathan L Shaw

Louis F Malice, Jr

Jack Griffis

Daiana Weiss

Colleen Kraft

Sungmun Lee

Systems, devices and methods are configured to prepare a specimen. A system may include a preparation device configured to mate with a specimen collection device. The preparation device may include an agitator member and a filter member. The filter member and the agitator member may be configured to move independently with respect to each other and the preparation platform member. The filter member may be configured to move linearly with respect to the preparation platform member and/or the agitator member, and the agitator member may be configured to move linearly and radially with respect to the preparation platform member and/or the agitator member. The system may also include a specimen collection device. The specimen may include but is not limited to fecal matter.

Systems, devices, and methods for specimen preparation

Delivery devices, systems, and methods are configured to enhance retention of a therapeutic agent delivered at a treatment site, for example, via impeding agent backflow. A device may include sheath having a first end, a second end, and a length between the first end and the second end. The sheath may include an outer diameter and an inner channel between the first end and the second end, and at least one penetrating member configured to form a channel at the treatment site. The device may include an elongate member having a first end, a second end, and a length between the first end and the second end, the elongate member being configured to move relative to the sheath. The elongate member may be configured to control the movement of the penetrating member with respect to the sheath.

Delivery devices, systems and methods for delivering therapeutic agents

Methods of manufacturing a three-dimensional, biodegradable, thermoset polymeric network composition having desirable degradation and mechanical properties, comprising a macromer component cross-linked with a monofunctional acrylate-containing component. The macromer component can comprise a diacrylate-containing component polymerized with an amine-containing component, wherein the molar ratio of the diacrylate-containing component to the amine-containing component is greater than or equal to 1.

Biodegradable polymeric networks and methods for manufacturing the same

The present disclosure is generally related to methods of preventing oxidative stress injury induced by renal ischemia-reperfusion by a Folate-TEMPOL conjugate.

Methods for preventing oxidative stress injury of a tissue by a Folate-TEMPOL conjugate

Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted &#x3c0; conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended &#x3c0; conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo.

Reduced dye probes for the detection of radical oxygen species

A medical practitioner can specify certain parameters for a procedure that involves delivering a therapeutic agent, while leaving other parameters open. The therapeutic agent can be sensitive to biomechanical forces (or other influences) associated with delivery. The procedure can involve regenerative medicine, for example delivering progenitor or stem cells to a diseased heart using a catheter, whereby unbridled transport in the catheter may compromise efficacy. The open parameters can influence efficacy of the agent and thus therapeutic outcome. A computer-based system can apply stored information, such as from databases, to narrow the possible values of the open parameters. From the narrowed possibilities, an optimization routine can determine suitable or optimized values for the open parameters. The determined values can manage biomechanical forces incurred by the therapeutic agent, thereby promoting efficacy and healing. The optimized parameters can guide the practitioner in the procedure.

Guided delivery of cell, particle, and drug based therapies

Method and system for mitigating effects of biomechanical forces on cell, particle and drug based therapies

A catheter for delivering a therapeutic agent to a target site of a human or animal subject can include a substantially flexible and biocompatible catheter body having a proximal end and a distal end. An eductor can be located at the distal end of the catheter body, and a first lumen within the catheter body for housing the therapeutic agent can be in fluid communication with the eductor. A second lumen, also in fluid communication with the first lumen, can extend from the proximal end of the catheter body towards the eductor and can have an output port at the distal end of the catheter body. The eductor can be operable to induce the therapeutic agent to flow from the first lumen out of the output port in response to fluid flowing through the second lumen.

System and method for delivering a therapeutic agent with finesse

A physician, nurse, or other healthcare practitioner can deliver a therapeutic agent to a patient in a manner that maintains effectiveness of the therapeutic agent, via monitoring and controlling shear, stress, or other potentially detrimental effect. A gauge, meter, or other monitoring device can provide an indication of shear (or other effect) that the therapeutic agent is experiencing during delivery. The monitoring device can provide information relevant to delivering the therapeutic agent in a manner that maintains effectiveness, thereby guiding the practitioner during delivery. For example, the monitoring device can display an estimate of shear based on sensing flow rate or pressure. The therapeutic agent can comprise one or more therapeutic cells, such as progenitor cells or stem cells, or some other healing substance delivered via a cardiac catheter to the patient's cardiovascular tissue, for example.

Growing community of inventors

Stone Mountain, GA, United States of America

W Robert Taylor